TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06230120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US)~External electrical pulse generator (Wireless External Neurostimulator System (WENS), Medtronic)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US) with external stimulator turned off
Study: NCT00814320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Description: Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous \[SC\] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Description: Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).
Study: NCT03220490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: no interval between regular glaucoma drops - Long term
Description: In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP reduction of Brimonidine and Timolol with time interval
Description: In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP reduction of Brimonidine and Timolol with time interval
Description: In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP reduction of Brimonidine and Timolol no time interval
Description: In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP reduction of Brimonidine and Timolol no time interval
Description: In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period.
Study: NCT00696748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebido (testosterone undecanoate)
Description: Nebido (testosterone undecanoate) intramuscular 4 ml by scheme

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 mL intramuscular
Study: NCT02481544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Journaling Plus SOC

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Memorable Events Journaling Plus SOC
Study: NCT01989026

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Study: NCT04102202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-DP-o-05
Description: BOL-DP-o-05

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03520166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium frequency electrotherapy (interferential currents)
Description: Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Description: No treatment
Study: NCT02506842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Patients receive oxaliplatin 85 mg/m\^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Patients receive folinic acid 200 mg/m\^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Patients receive fluorouracil 2000 mg/m\^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
Study: NCT04233476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2 injection
Description: A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
Study: NCT02294890

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Study: NCT03931148

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Geriatric Assesment with neuropsychological test more specific on decision making
Description: The following tests will be made : MoCA, FAB, TMT, Stroop-Victoria, JAT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional RMI
Description: With specific test of decision making (IGT) specially adapted to the population

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High Resolution EEG
Description: With specific test of decision making (BART) specially adapted to the population

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative interview
Description: Qualitative semi-directed interviews with participants, their caregivers and their geriatrician to analyse everyday life decision making ability.
Study: NCT00758238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myBP facilitated e-health self-management
Description: MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
Study: NCT03546881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fusion imaging guidance technology
Description: Imaging fusion guidance overlay used during PAOD endovascular revascularisation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D X-ray screen
Description: 2D X-ray screen during PAOD endovascular revascularisation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D X-ray screen
Description: 2D X-ray screen during PAOD endovascular revascularisation
Study: NCT05088070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH 3348
Description: 8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Study: NCT02384759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV5FU2
Study: NCT00698490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141
Description: Intramuscular injection, 3 doses, 2 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141
Description: Intramuscular injection, 3 doses, 2 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141
Description: Intramuscular injection, 3 doses, 2 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141
Description: Intramuscular injection, 3 doses, 2 different formulations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus containing gD-Alum
Description: Intramuscular injection, 3 doses
Study: NCT03871179

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ASD Diagnostic Device
Description: The ASD Diagnostic Device is a machine learning algorithm-based software as a medical device that is incorporated into a parent/caregiver-facing mobile application, the Cognoa App, used outside of a clinical setting
Study: NCT03496155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Build and Support Your Teen's Strengths
Description: This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Build and Support Your Teen's Strengths
Description: This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach.
Study: NCT02081573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT
Description: During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
Study: NCT03810625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0502
Description: D-0502 oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0502
Description: D-0502 oral tablets
Study: NCT04334265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anluohuaxian
Description: 6g each time, twice a day
Study: NCT01506895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: Experimental compound 160 mg dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo to match
Study: NCT03469323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
Study: NCT00571454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone depression care management
Description: 1 call per week for first 4 weeks~1 call every other week for next 8 weeks
Study: NCT00462215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
Description: Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
Study: NCT02767115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2% GSE mucoadhesive gel
Description: 2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GSE free mucoadhesive gel
Description: GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
Study: NCT02639260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl D-mannosamine
Description: dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl D-mannosamine
Description: dose escalation
Study: NCT02587442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RadProtect®
Description: This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
Study: NCT00500877

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Management Phone Counseling for Smoking Cessation
Description: Phone counseling addressed mood management and smoking cessation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mood Management Phone Counseling for Smoking Cessation
Description: Phone counseling addressed mood management and smoking cessation
Study: NCT03587246

Intervention type: DIAGNOSTIC_TEST
Intervention: 3DTVUS : Uterine peristaltic frequencies
Description: Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles

Intervention type: DIAGNOSTIC_TEST
Intervention: 3DTVUS : Uterine peristaltic frequencies
Description: Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
Study: NCT01443819

Intervention type: OTHER
Group type: OTHER
Intervention: Lumbar Transforaminal Epidural Corticosteroid Injection
Description: Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines.

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
Study: NCT01474096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implementation strategy of Breastfeeding
Description: implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
Study: NCT00345982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdolect
Description: 16 mg, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01171326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
Study: NCT00232830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent
Description: Cypher Sirolimus-eluting Coronary Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent
Description: any bare-metal stent brand
Study: NCT01463722

Intervention type: OTHER
Group type: OTHER
Intervention: Amniotic fluid Lamellar Body Counting
Description: fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
Study: NCT02664129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video self-observation
Description: Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non Self video observation
Description: Patients will not watch the video of them in acute decompensation phase.
Study: NCT05253248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OMIS
Description: This is an open-label micronutrient supplementation trial in healthy adult volunteers. We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days.
Study: NCT02693275

Intervention type: DEVICE
Group type: OTHER
Intervention: Quotient® System iPad Test
Description: See arm/group description